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Article focus
  Analysis of health-related quality of life 
(HRQol) after hip fracture including 
patients who died during follow-up ver-
sus survivors only.
Key messages
  When reporting HRQol using EuroQol-5D 
for patients after a hip fracture, excluding 
patients who die during follow-up leads 
to overly-optimistic estimates of patient 
outcomes and the effects of the treat-
ment pathway.
  We would recommend that ‘death-
adjusted’ estimates should be used rou-
tinely when reporting HRQol in this 
population.
Strengths and limitations
  This is a large study that reports highly 
significant differences between HRQol 
outcomes in this population.
  The main limitation is that all of the data 
were reported from a single trauma 
centre.
Introduction
Health-related quality of life (HRQol) is now 
the most widely used primary outcome 
measure for studies reporting outcomes for 
patients after hip fracture.1-5 The EuroQol-5 
Dimensions (EQ-5D) has become the pre-
ferred measure to determine HRQol in the 
United Kingdom and in many other coun-
tries.1,2,6-9 EQ-5D at four months after the 
Modelling and estimation of health-
related quality of life after hip fracture 
A RE-ANAlYsis of DATA fRom A pRospEcTivE coHoRT sTUDY
Objectives
This study investigates the reporting of health-related quality of life (HRQoL) in patients fol-
lowing hip fracture. We compare the relative merits and make recommendations for the use 
for two methods of measuring HRQoL; (i) including patients who died during follow-up and 
(ii) including survivors only.
Methods
The World Hip Trauma evaluation has previously reported changes in HRQoL using euroQol-
5D for patients with hip fractures. We performed additional analysis to investigate the effect 
of including or excluding those patients who died during the first four months of the follow-
up period.
Results
The dataset included 503 patients, 25 of whom died between 30 days and four months of 
injury. There was a statistically significant difference in 30-day HRQoL between those alive 
(mean 0.331 and standard deviation (sd) 0.360) and those dead (mean 0.156 and sd 0.421) 
by four months (independent-samples t-test; p 0.022). The estimated difference of 0.175 in 
HRQoL (95% confidence interval 0.025 to 0.325) was also highly clinically significant.
Conclusion
When reporting HRQoL for patients after a hip fracture, excluding patients who die during 
follow-up leads to an overestimate of the effects of the intervention or treatment pathway. 
We would recommend that death-adjusted estimates should be used routinely when report-
ing HRQoL in this population.
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fracture is part of the UK core outcome set for hip frac-
ture studies,10 which has been adopted by the National 
institute for Health and care in its most recent Hip 
fracture Guidelines.11
Hip fracture affects an older and often frail population. 
Griffin et al2 report conservative estimates of mortality in 
the United Kingdom population of approximately 12% at 
four months and 20% at one year for patients aged > 80 
years. in many areas of healthcare, patients who die 
before completing a study are often excluded from the 
primary analysis. This is, in general, not a particularly 
important issue if the number of patients who die is low. 
However, since the number of patients who die in the 
months following a hip fracture is relatively high, this 
approach inevitably leads to a loss of data and therefore 
a  loss of precision when estimating outcomes. it also 
potentially leads to biased analyses, as by excluding 
those patients who die early we are likely to produce 
unduly optimistic estimates of HRQol. one potential 
advantage of EQ-5D is that it provides, through the asso-
ciated health utilities, a natural value for study partici-
pants who died prior to an outcome assessment; EQ-5D 
is anchored at 1 for full health and 0 for death. By includ-
ing the important sub-group of patients who die in the 
months following hip fracture in the primary analysis 
of outcomes, we could therefore increase the precision of 
hip fracture studies. Hereafter, we refer to the inclusion of 
patients who died during follow-up as a ‘death-adjusted’ 
EQ-5D estimate, as opposed to a ‘complete-case’ esti-
mate, which is based on only those patients alive at the 
index assessment occasion (four months). However, if 
the patients who die early had high HRQol before their 
death, then assuming that their EQ-5D score was zero 
risks underestimating the potential benefits of an inter-
vention, even if the patient subsequently dies before 
reaching their four-month assessment.
in this study, we investigate the use of a death-adjusted 
EQ-5D score in the analysis of outcomes following hip frac-
ture. We undertake additional analysis of the data available 
from the World Hip Trauma Evaluation (WHiTE),1,2,4 which 
provided routine EQ-5D at four weeks, in addition to the 
four-month timepoint. These early outcome data allow us 
to model temporal changes in EQ-5D during the recovery 
phase, and to compare the relative merit of a death-
adjusted versus a complete-case EQ-5D estimation and 
make recommendations about which to use.
Materials and Methods
Data. We conducted a prospective longitudinal cohort 
study to assess HRQol at four weeks, four months and one 
year after hip fracture,4 referred to as the WHiTE study. in 
addition, a small convenience sample of the WHiTE study 
participants provided HRQol assessments immediately 
post-injury. All patients, or proxy respondents where 
appropriate, provided informed consent or agreement, 
respectively. The study is registered with current 
controlled Trials (isRcTN63982700) and full protocols 
have previously been published.4,12 The data in this study 
comes from participants who presented with a hip frac-
ture at a single major trauma centre in England between 
January 2012 and march 2014; those who were aged 
less than 60 years or who were managed  nonoperatively 
were excluded from the study. A full description of the 
totality of data collected is available elsewhere.2 Here we 
focus exclusively on the primary outcome measure, which 
was the EQ-5D score (EQ-5D-3l),6,7 a generic health util-
ity instrument used to measure HRQol. EQ-5D is a vali-
dated, cross-disciplinary standardized instrument that is 
widely used to assess HRQol after hip fracture. it has two 
parts: a visual analogue scale (vAs), which measures self-
rated health and a health status instrument consisting 
of a three-level response (no problems, some problems 
and extreme problems) for five health domains related to 
daily activities. These health domains are mobility, self-
care, usual activities, pain and discomfort and anxiety 
and depression. more recent data collected as part of the 
WHiTE study uses the 5l version of EQ-5D that provides 
greater sensitivity than the 3l. Responses from the EQ-5D 
health classifications were converted into an overall score 
using a published utility algorithm for the population of 
the United Kingdom.13
Statistical analysis. study data were summarized using 
means and standard deviations (sd), and visualized by 
box plots and strip plots to show variation in outcomes. 
independent-samples t-tests were used to draw inferences 
on mean differences between selected sub- populations. 
The complexity of the setting we describe here is that early 
death of study participants  postoperatively caused drop-
out (loss to follow-up), since no EQ-5D measurements 
were available after the terminal event for the four-month 
timepoint. if this dropout is non-random, then this is 
likely to cause bias in any analysis that ignores the drop-
out process. To obtain valid inferences, we use methods 
that allow fitting of joint models of longitudinal and time-
to-event (survival) data.14 The longitudinal model for the 
temporal changes in EQ-5D postoperatively was a mixed-
effects model that had a random additive participant 
effect, fixed effects for the baseline (pre-injury) EQ-5D 
and a quadratic  (second-order polynomial) model for the 
log-transformed  postoperative time. The survival data 
Table I. Age, gender split and baseline EuroQol 5 Dimensions (EQ-5D) for 
participants from the full World Hip Trauma Evaluation population (n = 741) 
and for those available for this study (n = 503)
Full population 
(n = 741)
Study population 
(n = 503)
mean age, yrs (sd) 83.1 (8.7) 82.8 (8.3)
Gender, female:male (% f) 503:186 (73.0) 362:117 (75.6)
mean baseline EQ-5D (sd) 0.559 (0.348) 0.574 (0.337)
sD, standard deviation
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was summarized  using a proportional-hazards (cox) 
model,15 adjusting for the baseline EQ-5D score. Joint 
models were fitted in the R package, Jm (R foundation, 
vienna, Austria),16,17 using a piecewise-constant baseline 
risk function and the Gauss-Hermite method for integral 
approximation.
Results
The totality of data available (n = 741) has been described 
previously and in full by Griffin et al;2 there were 118 
deaths reported during the course of study, with age, 
gender, American society of Anesthesiologists (AsA) 
grade,18 and preoperative Abbreviated mental Health 
score (AmTs)19 all being statistically significant predictors 
of survival.2 postoperative trends in EQ-5D varied by 
AmTs score (⩽ 8 and > 8) and age-group (⩽ 80 years 
and > 80 years); in summary, recovery was generally 
worse for those in the older group and those with lower 
AmTs.2 EQ-5D scores did not recover to baseline (pre-
injury) levels but followed a characteristic trajectory up to 
12 months, with little or no improvements after four 
months.2. Therefore, we focus our modelling work on 
this four-month period.
population characteristics. The full (baseline, four weeks, 
and four months) or partial (one or more of the values 
present) time courses of EQ-5D data were available from 
503 of the WHiTE study participants. The age distribu-
tion, gender split and baseline EQ-5D for this group was 
comparable with the full study population (Table i).
The study population consisted of 478 participants 
who survived to four months, and 25 who died after pro-
viding four-week EQ-5D data but before reaching the 
four-month follow-up timepoint. Table ii shows the char-
acteristics of these two groups.
A t-test indicated that the baseline EQ-5D was statisti-
cally significantly lower for those participants who were 
dead at four months than for those who were alive at this 
timepoint (p = 0.034); estimated difference 0.146 (95% 
ci 0.01 to 0.282).
figure 1 shows strip plots and box plots of four-week 
EQ-5D data; medians and interquartile ranges (iQRs) for 
the two groups are 0.290 (iQR 0.055 to 0.640) and -0.040 
(iQR -0.170 to 0.625). Evidence from previous analyses is 
that Gaussian approximations for EQ-5D are reasonable 
for this population;1,2 focusing on means and sds, a t-test 
shows that there was a statistically significant difference 
in four-week EQ-5D between those alive (mean 0.331 
and sd 0.360) and those dead (mean 0 .156 and sd 
0.421) by four months (t-test; p 0.022). The estimated 
difference 0.175 (95% ci 0.025 to 0.325) was also highly 
clinically significant (the minimum clinically important 
difference for EQ-5D is 0.074),20 and indicated (together 
with the significant difference in baseline EQ-5D) that low 
EQ-5D was strongly associated with postoperative death.
Complete-case analysis. The most widely used and rec-
ommended endpoint for EQ-5D in this population is at 
four months.2 When reporting results of this outcome 
for a randomized controlled trial (RcT), one approach 
to analysis is to simply report summary statistics (e.g. 
means and sds) based on the population of patients who 
are alive at the four-month timepoint. if we are willing 
to accept that withdrawals and losses due to participant 
deaths are not related to the interventions, then compar-
ing, for instance, group means at four months should 
provide an appropriate analysis, all else being equal.
Using EQ-5D data from only those participants alive at 
the four-month timepoint (n = 478) provides an estimate 
of the mean EQ-5D at four months of 0.454 (95% ci 
0.414 to 0.495).
Model-based prediction. it is clear from figure 1 and 
Table i that the characteristics of those participants who 
die early (before four months) are different from those 
who survive to provide EQ-5D assessments. Therefore, 
we proceed to fit joint models that enable us to explic-
itly allow for the effects of the underlying longitudinal 
EQ-5D outcome on the risk of death. in these models, 
we implicitly make the assumption that the complete 
EQ-5D longitudinal response (to the study endpoint at 
four months) is meaningful for all participants, including 
EQ-5D observations that would have been collected after 
death for those participants who died early.
one could argue that in this setting, as the terminating 
event is death, it makes no sense at all to consider the 
value of EQ-5D after death. However, for the purposes of 
exposition we proceed to fit models to the observed data 
and make predictions on future trends in EQ-5D scores 
for those study participants who died early. figure 2 
shows observed data and model fits for the full popula-
tion, for participants alive at four months, and for partici-
pants who were dead at four months. The projected 
EQ-5D for the population of early deaths (under the 
assumption that they did not die but progressed to the 
Table II. Age, gender split and baseline EuroQol 5 Dimensions (EQ-5D) for participants who were alive (n = 478) and for those dead (n = 25) by the four-month 
timepoint
Alive at 4 mths (n = 478) Dead at 4 mths (n = 25) p-value
mean age, yrs (sd) 82.7 (8.2) 85.8 (8.5) 0.062*
Gender, female:male (% f) 346:110 (75.9) 16:7 (69.6) 0.464†
mean baseline EQ-5D (sd) 0.581 (0.339) 0.434 (0.254) 0.034*
*independent-samples t-test
†fisher’s exact test
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four month timepoint) (fig. 2c) indicates that, for this 
group, EQ-5D was likely to remain lower than that of 
those patients who we know survived to four months. 
The predicted EQ-5D score at four months for the dead 
group (n = 25) was 0.349 (95% ci 0.260 to 0.438) and 
for the alive group was 0.445 (95% ci 0.425 to 0.464); 
there was a statistically significant difference between 
groups based on an independent-samples t-test of pre-
dictions at four months (p-value = 0.034).
Using EQ-5D data from the full population (n = 503), 
then building a model to predict and project how those 
participants who died early may have progressed if they 
did not die, provides an estimate of the mean EQ-5D at 
four months of 0.440 (95% ci 0.421 to 0.459).
Death-adjusted analysis. Rather than attempt to model 
and project changes in EQ-5D scores from months one to 
four for those patients who did not survive to the study 
endpoint (the dashed line in fig. 2c), a simpler approach 
is to assume that EQ-5D becomes zero at death, and then 
carry this observation forward to subsequent assessment 
occasions. We call this ‘death-adjusted’ EQ-5D.2
Undertaking this analysis for the WHiTE study popula-
tion provides an estimate of the mean EQ-5D at four 
months of 0.424 (95% ci 0.384 to 0.464).
Discussion
Three methods of summarising EQ-5D at four months 
postoperatively have been presented for patients after 
hip fracture. The first method (complete-case analysis) 
summarizes outcomes at four months using data only for 
those patients who were alive at this timepoint. Estimates 
of mean EQ-5D using this method (0.454; 95% ci 
0.414 to 0.495) were larger than the other two methods 
discussed. This is not an unexpected result, as we show 
that those patients who died before four months had sig-
nificantly lower EQ-5D at the early four-week assessment. 
By modelling the observed temporal changes in EQ-5D, 
we attempt to predict what the EQ-5D would have been 
for these participants who died early, if they had survived 
to four months. This model-based prediction provided an 
estimate of mean EQ-5D at four months (0.440; 95% ci 
0.421 to 0.459) that was lower than the complete-case 
method. Even if we assume that, for those who died, the 
cause of death was not directly related to the interven-
tion, we conclude that the complete-case method pro-
vides positively biased estimates of EQ-5D (i.e. it tends to 
overestimate the measure). Therefore, we would not 
generally recommend the complete-case analysis unless 
the focus of a study is purely on outcomes for those par-
ticipants who survived to the study endpoint. if this is the 
case, then some inflation to the sample size should be 
made to allow for postoperative losses due to death.
The death-adjusted analysis method provided esti-
mates of EQ-5D (0.424; 95% ci 0.384 to 0.464) that 
were lower still than the model-based prediction 
method. Again, this is not unexpected, as we have 
replaced the missing four-month data for individuals 
who died prior to the four month assessment (n = 25) 
with values of zero, which were always lower than the 
model-based predictions. A paired t-test indicated that 
death-adjusted EQ-5D estimates were statistically sig-
nificantly smaller than corresponding model-based 
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Fig. 1
strip plots and box plots of four-week EuroQol 5 Dimensions (EQ-5D) data. 
for those World Hip Trauma Evaluation study participants alive (n = 478) and 
those who died (n = 25) at four months postoperatively. stacked bars show 
numbers of participants for each EQ-5D score and box plots show interquar-
tile range (iQR; box), median (solid line) and whiskers at 1.5 times the iQR.
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Fig. 2a Fig. 2b Fig. 2c
longitudinal models for postoperative EuroQol 5 Dimensions (EQ-5D) from 
the full World Hip Trauma Evaluation study population (n = 503) (a), for par-
ticipants alive at four months (n = 478) (b) and for participants who had died 
at four months (n = 25) (c). observed means are plotted, with 95% confi-
dence intervals (bars) and also fitted curves with 50% confidence regions.
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predictions (p-value = 0.037), although the difference 
(paired mean difference in EQ-5D is 0.027) was such as 
to be clinically unimportant.20
Due to the lack of clinically important difference 
between these methods of estimation, because the death-
adjusted analysis method is considerably simpler than 
the model-base method, and because the assumptions 
required for the model-based method are unlikely to be 
met (i.e. that participants could have survived to provide 
observations at the index four-month timepoint), we rec-
ommend that death-adjusted estimates should be rou-
tinely used for reporting HRQol in this population.
one could argue that, for comparative analyses (i.e. 
comparing groups A and B in a RcT), in principle it is not 
necessarily important whether estimates of EQ-5D are 
biased, as we are only interested in differences between 
groups. This is a weak argument, as if one knows that 
estimates of EQ-5D are likely to be positively biased, then 
it is difficult to justify not attempting a correction. 
Reporting death-adjusted EQ-5D also provides the addi-
tional benefit of increasing the sample size, as we no 
longer need to discard participants who have died prior 
to the study endpoint. However, experience suggests 
that the death-adjusted estimator has a larger variance 
than the complete-case estimator, due to the inclusion of 
the zero scores, which are not typically located at the 
mean of the distribution. Therefore, some inflation of the 
sd, relative to previously reported values based on 
 complete-cases,5 should be considered when calculating 
study sample sizes. it should be noted that the model-
based approach provided tighter confidence intervals 
than either of the other methods discussed, as it uses full 
information for estimation and it imposes constraints on 
the form of the longitudinal model for EQ-5D.
in conclusion, when reporting HRQol for patients after 
a hip fracture, excluding patients who die during follow-
up leads to an overly optimistic estimation of the effects of 
the intervention or treatment pathway. We would recom-
mend that death-adjusted estimates should be routinely 
used for reporting HRQol in this population.
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